STARTUP PROFILE

Paradromics

COUNTRY
USA
FOUNDED
2016
CATEGORY
Brain-Computer Interface
Developing the Connexus, a fully implantable, high–data-rate BCI that records single-neuron brain signals to restore communication in paralyzed patients.
Visit website →
Market Notes · Biweekly

Track this company

Funding, launches and regulatory moves across the neurotech startup map.

Subscribed. Check your inbox to confirm.

•
Neurofounders Insights
$   Funding   -
Series B
MODALITY
Intracortical
FORM FACTOR
Implant
INTERFACE DEPTH
Implantable
INDICATION
Communication
TARGET USER
Patients
REGULATORY STAGE
Investigational
Paradromics is one of the most serious competitors in the high-bandwidth implantable BCI category, emphasizing single-neuron recording and communication restoration. It is often framed as a peer to Neuralink, though with a more tightly defined initial use case and lower public visibility.
•
Mentioned in Market Notes
MOST RECENT COVERAGE
#
9
BCI Shows its Value
1 September – 15 September 2026

The first participant implanted with Paradromics' Connexus brain-computer interface has successfully used the device for real-time speech. The Michigan woman, in her sixties and living with motor neuron disease, chose her own words, answered open-ended questions, and spoke with her grandchildren on a phone call. According to the startup, every word directly reflected her selections, without corrections. The milestone comes three months after implantation as part of Paradromics' Connect-One feasibility study.

#
8
FDA Supports the BCI Mission
18 August – 1 September 2026

Paradromics received FDA approval to connect its investigational Connexus brain-computer interface to patients' own laptops, tablets, and phones. Until now, the implant worked only with a company-provided computer. The approval moves the platform toward the technology patients already use daily. It applies within the ongoing Connect-One feasibility study, the first for a fully implantable BCI aimed at restoring speech.

Articles featuring
Paradromics